29. (Reiterated) The method of claim 26, wherein the prosaposin receptor agonist is selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.

30. (Reiterated) The method of claim 26, wherein the contacting is *in vitro*.

31. (Reiterated) The method of claim 26, wherein the contacting is *in vivo*.

IN THE SPECIFICATION:

In the DETAILED DESCRIPTION OF THE INVENTION, page 11, line 10, after "sequence", please replace "$LIRX_1NNX_2TX_3X_4X_3X_1X_1$," with -$LIX_1NNX_2TX_3X_4X_3X_1X_1$,- (SEQ ID NO:25).

REMARKS

These amendments are made to correct a typographical error. No new matter is added.

In transcribing the inventors notations, where "R" is an amino acid, to notation where "X" is an amino acid, the drafter unintentionally omitted a change from "R" to "X_1". This unintentional omission resulted in a duplication of amino acids, "RX_1".

Support for the amendments is found in the examples of "$LIRX_1NNX_2TX_3X_4X_3X_1X_1$" provided in the DETAILED DESCRIPTION, page 11, lines 13 to 22. The examples are:

> The prosaposin receptor agonist preferably contains the amino acid sequence Leu-Ile-Asp-Asn-Asn-Lys-Thr-Glu-Lys-Glu-Ile-Leu (SEQ ID NO:3), which corresponds to amino acids 18 to 29 of saposin C. More preferably, an active fragment of prosaposin has the amino acid sequence Cys-Glu-Phe-Leu-Val-Lys-Glu-Val-Thr-Lys-Leu-Ile-Asp-Asn-Asn-Lys-Thr-Glu-Lys-Glu-Ile-Leu (SEQ ID NO:1), which corresponds to amino acids 8 to 29 of saposin C, or the amino acid sequence Thr-D-Ala-Leu-Ile-Asp-Asn-Asn-Ala-Thr-Glu-Glu-Ile-Leu-Tyr (SEQ ID NO:2), which corresponds to amino acids 16 to 29 of saposin C but which has been modified by a D-alanine for lysine substitution at position 2; an alanine for lysine substitution at position 8; a deletion of lysine at position 11 and the addition of a C-terminal tyrosine residue (*see* TABLE 2).

As can be seen by inspection, SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 are not example of $LIRX_1NNX_2TX_3X_4X_3X_1X_1$. However, these SEQ ID NOS are examples of $LIX_1NNX_2TX_3X_4X_3X_1X_1$,

Further support is found in TABLE 3, page 13, and the accompanying disclosure on page 12, lines 7 to 20. As can be seen by inspection, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7 are not examples of $LIRX_1NNX_2TX_3X_4X_3X_1X_1$. However, these SEQ ID NOS are examples of $LIX_1NNX_2TX_3X_4X_3X_1X_1$.

Further support is found in TABLE 4, page 14, and the accompanying disclosure on page 13, lines 8 to 17, which discuss the "well-conserved adjacent asparagine residues, leucine residue and charged residues [which] can be important for the activity of an active fragment of prosaposin in alleviating neuropathic pain." As can be seen by inspection, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10 are derivatives of $LIX_1NNX_2TX_3X_4X_3X_1X_1$. *Note,* the underlined amino acids in TABLE 4. However, these SEQ ID NOS are not derivatives of $LIRX_1NNX_2TX_3X_4X_3X_1X_1$.

Further support is found in the original claims 2, 11, 20, and 28. These claims all recite that $LIRX_1NNX_2TX_3X_4X_3X_1X_1$ has the amino acid sequence shown in SEQ ID NO:2. As can be seen by inspection, $LIRX_1NNX_2TX_3X_4X_3X_1X_1$ cannot have the amino acid sequence shown in SEQ ID NO:2. However, $LIX_1NNX_2TX_3X_4X_3X_1X_1$ can have the amino acid sequence shown in SEQ ID NO:2.

If the Examiner would like to discuss any of the amendments, Applicant's representative can be reached at (619) 678-5070.

Please charge any additional fees, or make any credits, to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 12/22/97

John R. Wetherell, Jr., Ph.D.
Reg. No. 31,678
Attorney for Applicant

Fish & Richardson P.C.
4225 Executive Square, Suite 1400
La Jolla, CA 92037

Telephone: (619) 678-5070
Facsimile: (619) 678-5099

45859.LJ1